Cellebrite DI combines double-digit growth and an attractive valuation, positioning the stock for a potential reversal of its multiyear downtrend. Q3 revenue rose 18% to $149 million and ARR increased 20% to $528.5 million, supported by federal and international demand. CLBT raised 2026 adjusted EBITDA guidance to $163 million–$166 million.

